Welcome to our dedicated page for Galmed Pharmaceu news (Ticker: GLMD), a resource for investors and traders seeking the latest updates and insights on Galmed Pharmaceu stock.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company centered on the development of its lead candidate, Aramchol, for liver, cardiometabolic and gastrointestinal (GI) oncological indications. The GLMD news feed on Stock Titan aggregates company-issued updates, press releases and related coverage so readers can follow how Galmed’s Aramchol program and corporate strategy evolve over time.
News about Galmed frequently covers clinical and preclinical results for Aramchol. Recent announcements include meaningful top-line data from the AM-001 Phase 1 bioavailability study of Aramchol meglumine, as well as mechanism-of-action work in GI cancer models where combinations of Aramchol, Stivarga (regorafenib) and metformin significantly enhanced GI tumor cell killing in vivo and in vitro. Other items highlight Aramchol’s Phase 3-ready status in MASH/NASH and fibrosis and its positioning as an SCD1 down-regulator.
Investors can also use the GLMD news page to monitor intellectual property developments, such as new use patents covering Aramchol in combination with Rezdiffra (resmetirom) for MASH and liver fibrosis across multiple jurisdictions. Financial and corporate updates appear as well, including quarterly financial results, capital raises through at-the-market facilities, changes in authorized share capital, and Galmed’s adoption of a digital asset management strategy overseen by a Board-level Crypto Committee.
Because Galmed is pursuing Aramchol across liver disease, oncology and cardiometabolic areas, news items often provide insight into how the company prioritizes indications, structures collaborations with academic centers, and interprets biomarker findings from studies like ARMOR. Bookmark this page to review new GLMD press releases, SEC-linked announcements and scientific updates in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has filed its Annual Report on Form 20-F for the fiscal year ending December 31, 2022, with the SEC. The report details their development of Aramchol for liver diseases and includes risks associated with clinical trials and regulatory approvals. Shareholders can access the report via the SEC and the company's Investor Relations website. Galmed remains focused on advancing Aramchol and collaborating on the development of other therapies, including Amilo-5MER.
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced that the U.S. Patent and Trademark Office granted patent 11,571,431 B2, extending Aramchol's exclusivity to December 2034. This patent protects Aramchol's use, particularly in treating NASH and Fibrosis, and fortifies its existing patent portfolio, which now encompasses over 20 issued patents worldwide. The N-methylglucamine salt form, noted for its advantageous properties, enhances absorption and bioavailability. CEO Allen Baharaff emphasized that this patent strengthens their ability to maximize Aramchol's therapeutic potential across various indications.
FAQ
What is the current stock price of Galmed Pharmaceu (GLMD)?
What is the market cap of Galmed Pharmaceu (GLMD)?
